[HTML][HTML] First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - Elsevier
Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
[引用][C] First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - cir.nii.ac.jp
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN JOURNAL …, 2020 - iris.unito.it
Background: Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN JOURNAL …, 2020 - air.unipr.it
Background: Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN JOURNAL …, 2020 - iris.univr.it
Background: Pembrolizumab is the first-line standard of care for advanced non-small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) >= 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) >= 50%. Eastern …
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN …, 2020 - boa.unimib.it
Background: Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi… - … journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Pembrolizumab is the first-line standard of care for advanced non-small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - europepmc.org
Background Pembrolizumab is the first-line standard of care for advanced non-small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN …, 2020 - iris.univpm.it
Background: Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - EUROPEAN JOURNAL …, 2020 - cris.unibo.it
Background: Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …